{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:59:07Z","timestamp":1773212347659,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.leukres.2004.04.015","type":"journal-article","created":{"date-parts":[[2004,9,8]],"date-time":"2004-09-08T14:33:15Z","timestamp":1094653995000},"page":"3-9","source":"Crossref","is-referenced-by-count":26,"title":["A phase-I clinical trial of active immunotherapy for acute leukemia using inactivated autologous leukemia cells mixed with IL-2, GM-CSF, and IL-6"],"prefix":"10.1016","volume":"29","author":[{"given":"Wang-Gang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Hu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Mei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin-Xia","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Rong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2004.04.015_BIB1","doi-asserted-by":"crossref","unstructured":"Norbert CG, Elihu E, Richard JJ, Hyam IL, Ivan B, Shimon S. New developments in the therapy of acute myelocytic leukemia. Hematology 2000; pp. 69\u201389.","DOI":"10.1182\/asheducation-2000.1.69"},{"key":"10.1016\/j.leukres.2004.04.015_BIB2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1034\/j.1600-0609.2003.00065.x","article-title":"New approaches in the immunotherapy of haematological malignancies","volume":"70","author":"Costello","year":"2003","journal-title":"Eur. J. Haematol"},{"key":"10.1016\/j.leukres.2004.04.015_BIB3","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/blood.V95.7.2426","article-title":"Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease","volume":"95","author":"Anderson","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2004.04.015_BIB4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/978-3-642-81685-7_8","article-title":"Therapeutic effectiveness of neuraminidase-treated allogeneic myeloblasts as immunogen in acute myelocytic leukemia","volume":"80","author":"Bekesi","year":"1982","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.leukres.2004.04.015_BIB5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1365-2141.1990.tb02667.x","article-title":"Adjuvant immunotherapy with BCG of acute myeloid leukemia: a 15-year follow-up","volume":"75","author":"Reizenstein","year":"1990","journal-title":"Br. J. Haematol"},{"key":"10.1016\/j.leukres.2004.04.015_BIB6","first-page":"88","article-title":"Adjuvant immune stimulation with Corynebacterium parvum during maintenance chemotherapy of acute myeloid leukemia. A prospective randomized study","volume":"16","author":"Cour Petersen","year":"1983","journal-title":"Cancer Immunol. Immunother"},{"key":"10.1016\/j.leukres.2004.04.015_BIB7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1517\/14728214.8.2.489","article-title":"Cancer vaccines entering Phase III clinical trials","volume":"8","author":"Durrant","year":"2003","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.leukres.2004.04.015_BIB8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-2141.2003.03930.x","article-title":"Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin-2 in a myeloma model","volume":"120","author":"Stritzke","year":"2003","journal-title":"Br. J. Haematol"},{"key":"10.1016\/j.leukres.2004.04.015_BIB9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2141.1991.tb08615.x","article-title":"Treatment of acute myeloid leukaemia patients with recombinant interleukin-2: a pilot study","volume":"77","author":"Foa","year":"1991","journal-title":"Br. J. Haematol"},{"key":"10.1016\/j.leukres.2004.04.015_BIB10","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1182\/blood.V84.7.2158.2158","article-title":"Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia","volume":"84","author":"Meloni","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2004.04.015_BIB11","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/blood.V91.1.222","article-title":"Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent anti-tumor immunity compared with B7 family and other cytokine vaccines","volume":"91","author":"Dunussi-Joannopoulos","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2004.04.015_BIB12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1034\/j.1600-065X.2002.18813.x","article-title":"GM-CSF-based cancer vaccines","volume":"188","author":"Dranoff","year":"2002","journal-title":"Immunol. Rev"},{"key":"10.1016\/j.leukres.2004.04.015_BIB13","doi-asserted-by":"crossref","unstructured":"Kitahara M, Kishimoto S, Hirano T, Kishimoto T, Okada. The in vivo anti-tumor effect of human recombinant interleukin-6. Jpn J Cancer Res 1990;81:1032\u20131038.","DOI":"10.1111\/j.1349-7006.1990.tb03342.x"},{"key":"10.1016\/j.leukres.2004.04.015_BIB14","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/ijc.2910530518","article-title":"Combined therapy with IL-6 and inactivated tumor cells suppresses metastasis in mice bearing 3LL lung carcinomas","volume":"53","author":"Katz","year":"1993","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.leukres.2004.04.015_BIB15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3109\/10428199609052418","article-title":"Potential use of recombinant human interleukin-6 in clinical oncology","volume":"20","author":"Veldhuis","year":"1996","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2004.04.015_BIB16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1023\/A:1006357424124","article-title":"Interleukin-6 transduction of a rat T9 glioma clone results in attenuated tumorigenicity and induces glioma immunity in Fischer F344 rats","volume":"45","author":"Graf","year":"1999","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.leukres.2004.04.015_BIB17","unstructured":"Zhao W, Zhang W, He A, Wang Y, Yipingeng G, Tian W, et al. Cellular immunity effect of leukemia vaccine on tumor burdon rat. ACAD J XJTU 2003;15:51\u201354"},{"key":"10.1016\/j.leukres.2004.04.015_BIB18","first-page":"17","article-title":"The evidence for interleukin-6 as an autocrine growth factor in malignancy","volume":"3","author":"Akira","year":"1992","journal-title":"Semin. Cancer Biol"},{"key":"10.1016\/j.leukres.2004.04.015_BIB19","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/sj.onc.1206226","article-title":"Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway","volume":"22","author":"Wei","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2004.04.015_BIB20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood.V100.1.230","article-title":"Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6","volume":"100","author":"Ratta","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2004.04.015_BIB21","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1126\/science.1078231","article-title":"Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells","volume":"14","author":"Pasare","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.leukres.2004.04.015_BIB22","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1126\/science.1082031","article-title":"Immunology. Regulating the regulators","volume":"299","author":"Powrie","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.leukres.2004.04.015_BIB23","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/sj.onc.1204180","article-title":"The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells","volume":"20","author":"Ozbek","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2004.04.015_BIB24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00002371-200105000-00003","article-title":"Anti-tumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells","volume":"24","author":"Kinoshita","year":"2001","journal-title":"J. Immunother"},{"key":"10.1016\/j.leukres.2004.04.015_BIB25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/10428199909169607","article-title":"The role of T cell costimulation by CD80 in the initiation and maintenance of the immune response to human leukemia","volume":"35","author":"Matsumoto","year":"1999","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2004.04.015_BIB26","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/sj.leu.2402582","article-title":"Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD80 and GM-CSF: effects on proliferation, differentiation, and stimulation of allogeneic and autologous anti-leukemia immune responses","volume":"16","author":"Koya","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2004.04.015_BIB27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0145-2126(03)00058-4","article-title":"Restimulation of tumour-specific immunity in a patient with AML following injection with B7-1 positive autologous blasts","volume":"27","author":"Hicks","year":"2003","journal-title":"Leuk. Res"},{"key":"10.1016\/j.leukres.2004.04.015_BIB28","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood.V97.10.3138","article-title":"Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells","volume":"97","author":"Notter","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2004.04.015_BIB29","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood.V97.8.2420","article-title":"The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses","volume":"97","author":"Runyon","year":"2001","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2004.04.015_BIB30","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood.V85.9.2507.bloodjournal8592507","article-title":"Role of B7-1 in mediating an immune response to myeloid leukemia cells","volume":"85","author":"Matulonis","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2004.04.015_BIB31","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/sj.leu.2402710","article-title":"Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts","volume":"16","author":"Mohty","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2004.04.015_BIB32","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/sj.leu.2403014","article-title":"Identification of CD14 as a predictor for leukemic dendritic cell differentiation in acute myeloid leukemia","volume":"17","author":"van de Loosdrecht","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2004.04.015_BIB33","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/sj.leu.2402706","article-title":"Identification of precursors of leukemic dendritic cells differentiated from patients with acute myeloid leukemia","volume":"16","author":"Mohty","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2004.04.015_BIB34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.1989.tb07747.x","article-title":"Diagnostic and prognostic significance of myelomonocytic cell surface antigens in acute myeloid leukaemia","volume":"73","author":"Merle-Beral","year":"1989","journal-title":"Br. J. Haematol"},{"key":"10.1016\/j.leukres.2004.04.015_BIB35","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/sj.leu.2402943","article-title":"Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT Cells","volume":"17","author":"Metelitsa","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2004.04.015_BIB36","first-page":"355","article-title":"Construction and significance of directional expression cDNA library from myeloid leukemia cell line U937","volume":"11","author":"Chen","year":"2003","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.leukres.2004.04.015_BIB37","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/bjc.1978.37","article-title":"Active immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions","volume":"37","author":"Harris","year":"1978","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.leukres.2004.04.015_BIB38","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1080\/1042819021000032926","article-title":"The combination of chemotherapy and systemic immunotherapy and the concept of cure in murine leukemia and lymphoma","volume":"43","author":"Dunussi-Joannopoulos","year":"2002","journal-title":"Leuk. Lymphoma"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212604001845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212604001845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T03:39:34Z","timestamp":1585885174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212604001845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0145212604001845"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2004.04.015","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}